Payment overview · 2025
General Payments
$144.38
8 reported records · 6 companies
Healthcare provider profile · identity verified
Michael Emmit Collier, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FORT MYERS, FL · NPI 1164420394
Verified facts
What the public records show
CMS Open Payments records show Michael Emmit Collier, MD received $144.38 in general payments during 2025 across 8 reported records.
ABBVIE INC. accounted for 27.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 702 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.23 | 27.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.41 | 21.8% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $22.22 | 15.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.34 | 13.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.89 | 11.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.29 | 9.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $144.38 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $40.23 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 59 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
702 | 97 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1140 | 261 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1123 | 240 |
| Amlodipine Besylate | Amlodipine Besylate | 954 | 234 |
| Eliquis | Apixaban | 702 | 97 |
| Lisinopril | Lisinopril | 571 | 143 |
| Metoprolol Tartrate | Metoprolol Tartrate | 568 | 135 |
| Losartan Potassium | Losartan Potassium | 541 | 140 |
| Gabapentin | Gabapentin | 536 | 126 |
| Metoprolol Succinate | Metoprolol Succinate | 528 | 132 |
| Pantoprazole Sodium | Pantoprazole Sodium | 502 | 127 |
| Tamsulosin Hcl | Tamsulosin Hcl | 417 | 119 |
| Metformin Hcl | Metformin Hcl | 393 | 103 |
| Simvastatin | Simvastatin | 375 | 98 |
| Omeprazole | Omeprazole | 361 | 106 |
| Alprazolam | Alprazolam | 355 | 73 |
| Clopidogrel | Clopidogrel Bisulfate | 349 | 76 |
| Donepezil Hcl | Donepezil Hcl | 349 | 75 |
| Trazodone Hcl | Trazodone Hcl | 343 | 88 |
| Furosemide | Furosemide | 333 | 86 |
| Potassium Chloride | Potassium Chloride | 317 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 278 | 82 |
| Sertraline Hcl | Sertraline Hcl | 263 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 235 | 58 |
| Tramadol Hcl | Tramadol Hcl | 220 | 46 |
| Torsemide | Torsemide | 218 | 65 |
| Memantine Hcl | Memantine Hcl | 202 | 37 |
| Allopurinol | Allopurinol | 194 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 185 | 43 |
| Mirtazapine | Mirtazapine | 184 | 51 |
| Xarelto | Rivaroxaban | 176 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 173 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 172 | 50 |
| Divalproex Sodium | Divalproex Sodium | 170 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 169 | 44 |
| Carvedilol | Carvedilol | 164 | 49 |
| Famotidine | Famotidine | 160 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 154 | 32 |
| Buspirone Hcl | Buspirone Hcl | 139 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 132 | 32 |
| Januvia | Sitagliptin Phosphate | 131 | 16 |
| Atenolol | Atenolol | 129 | 32 |
| Ezetimibe | Ezetimibe | 125 | 28 |
| Jardiance | Empagliflozin | 122 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 120 | 25 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 118 | 18 |
| Clonazepam | Clonazepam | 117 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 117 | 34 |
| Prednisone | Prednisone | 117 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 42 |
| Finasteride | Finasteride | 106 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 105 | 24 |
| Lorazepam | Lorazepam | 105 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 104 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 103 | 23 |
| Spironolactone | Spironolactone | 103 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 101 | 66 |
| Lactulose | Lactulose | 98 | 19 |
| Montelukast Sodium | Montelukast Sodium | 96 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 94 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 93 | 22 |
| Warfarin Sodium | Warfarin Sodium | 93 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 26 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 92 | 41 |
| Levetiracetam | Levetiracetam | 87 | 18 |
| Meloxicam | Meloxicam | 86 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 81 | 22 |
| Myrbetriq | Mirabegron | 78 | 14 |
| Benazepril Hcl | Benazepril Hcl | 77 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 76 | 56 |
| Fenofibrate | Fenofibrate | 76 | 18 |
| Alendronate Sodium | Alendronate Sodium | 75 | 18 |
| Digoxin | Digoxin | 75 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 74 | 40 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 73 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 17 |
| Sucralfate | Sucralfate | 71 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 70 | 15 |
| Celecoxib | Celecoxib | 68 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 68 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 68 | 14 |
| Midodrine Hcl | Midodrine Hcl | 67 | 21 |
| Azithromycin | Azithromycin | 66 | 36 |
| Ondansetron Hcl | Ondansetron Hcl | 64 | 37 |
| Bumetanide | Bumetanide | 63 | 12 |
| Meclizine Hcl | Meclizine Hcl | 63 | 28 |
| Valsartan | Valsartan | 63 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | 13 |
| Baclofen | Baclofen | 62 | 24 |
| Bupropion Xl | Bupropion Hcl | 62 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 61 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 61 | 17 |
| Gemtesa | Vibegron | 61 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | 20 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 59 | suppressed |
| Ozempic | Semaglutide | 59 | 11 |
| Temazepam | Temazepam | 59 | 11 |
| Diazepam | Diazepam | 58 | 12 |
| Methocarbamol | Methocarbamol | 58 | 19 |
| Ceftriaxone | Ceftriaxone Sodium | 57 | 32 |
| Entresto | Sacubitril/Valsartan | 54 | suppressed |
| Ondansetron Odt | Ondansetron | 54 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | 13 |
| Trulicity | Dulaglutide | 53 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 52 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 25 |
| Synthroid | Levothyroxine Sodium | 51 | 11 |
| Gemfibrozil | Gemfibrozil | 50 | 11 |
| Nitroglycerin | Nitroglycerin | 50 | 33 |
| Latanoprost | Latanoprost | 49 | suppressed |
| Mupirocin | Mupirocin | 48 | 23 |
| Propranolol Hcl | Propranolol Hcl | 48 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | suppressed |
| Ibuprofen | Ibuprofen | 45 | 15 |
| Oxcarbazepine | Oxcarbazepine | 45 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 44 | suppressed |
| Tradjenta | Linagliptin | 44 | suppressed |
| Vascepa | Icosapent Ethyl | 44 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 43 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 43 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | 11 |
| Nystatin | Nystatin | 42 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 41 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 40 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Cephalexin | Cephalexin | 39 | 20 |
| Ketoconazole | Ketoconazole | 39 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 38 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 16 |
| Levofloxacin | Levofloxacin | 38 | 24 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | suppressed |
| Brilinta | Ticagrelor | 37 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 37 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 24 |
| Glimepiride | Glimepiride | 36 | suppressed |
| Topiramate | Topiramate | 36 | 11 |
| Methylprednisolone | Methylprednisolone | 35 | 31 |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 34 | 29 |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Glipizide Er | Glipizide | 33 | suppressed |
| Imipenem-Cilastatin Sodium | Imipenem/Cilastatin Sodium | 33 | suppressed |
| Movantik | Naloxegol Oxalate | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Primidone | Primidone | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 26 |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Ertapenem | Ertapenem Sodium | 32 | 17 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 32 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 32 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Insulin Lispro | Insulin Lispro | 31 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 31 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Permethrin | Permethrin | 29 | 17 |
| Rytary | Carbidopa/Levodopa | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Calcitriol | Calcitriol | 28 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 28 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 28 | 11 |
| Lovastatin | Lovastatin | 28 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Restasis | Cyclosporine | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 15 |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 23 |
| Ranolazine Er | Ranolazine | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Insulin Aspart | Insulin Aspart | 25 | 11 |
| Irbesartan | Irbesartan | 25 | suppressed |
| Ivermectin | Ivermectin | 25 | 15 |
| Rezvoglar Kwikpen | Insulin Glargine-Aglr | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 24 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 24 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 15 |
| Letrozole | Letrozole | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Xtampza Er | Oxycodone Myristate | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 22 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Cholestyramine Light | Cholestyramine | 21 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Lumigan | Bimatoprost | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Amantadine | Amantadine Hcl | 19 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 11 |
| Dulera | Mometasone/Formoterol | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Testosterone | Testosterone | 19 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Creon | Lipase/Protease/Amylase | 18 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Erythromycin | Erythromycin Base | 17 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Cefdinir | Cefdinir | 13 | suppressed |
| Cyclosporine | Cyclosporine | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Oxazepam | Oxazepam | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Travoprost | Travoprost | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $144.38 · 8 records | ABBVIE INC. | FUROSCIX, NEXLETOL, Ozempic, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, VYNDAQEL | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error